News -

Download the New Scientific Poster on iLite™ VEGF Assay Ready Cell line now!

The signaling protein Vascular Endothelial Growth Factor (VEGF) is a major contributor to angiogenesis in both health and disease. Since angiogenesis is required for tumour growth and metastasis, drugs targeting VEGF have been increasingly employed in a vast number of cancer therapies.

This new exciting iLite™ VEGF cell line that is intended to be used within the immune-oncology area has been genetically engineered to specifically detect VEGF activity, VEGF inhibitors and can be used to determine neutralizing antibodies against inhibitor drugs in human serum.

For more information, please see the iLite™ product page, and keep an eye out for more news regarding our iLite™ cell lines!

Click to download the poster "Quantification of Bevacizumab Activity and Anti-Bevacizumab Neutralizing Antibodies in a Cohort of Patients with Glioblastoma".

Related links

Topics

  • Diseases

Categories

  • ilite cell-based assays

Contacts

Related media

  • Download the New Scientific Poster on iLite™ VEGF Assay Ready Cell line now!
    License:
    All rights reserved
    File format:
    .pdf
    more info...

Related content

  • Announcing the launch of iLite™ VEGF Assay Ready Cells

    The launch of iLite™ VEGF Assay Ready Cells marks the first iLite™ reporter gene assay for use within the immuno-oncology area. The cells have been genetically engineered to specifically detect VEGF activity, and can be used to measure the potency of VEGF inhibitor drugs, as well as neutralizing antibodies against such drugs in human serum.

  • New research on cell-based reporter gene iLite™ assays

    The 10th International Congress on Autoimmunity is taking place in Leipzig, Germany April 6-10. The event provides an opportunity to hear about the hot topics in autoimmunity and discuss the newest therapeutic techniques and diagnostic tools as well as the most up-to-date research. We are happy to announce that we will hold a presentation relating to the use of a cell-based reporter gene assay.

Enter your email address to follow Euro Diagnostica AB

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Euro Diagnostica AB.

Okay